194 related articles for article (PubMed ID: 16257312)
1. Future of ophthalmic anti-infective therapy and the role of moxifloxacin ophthalmic solution 0.5% (VIGAMOX).
Schlech BA; Blondeau J
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S64-7. PubMed ID: 16257312
[TBL] [Abstract][Full Text] [Related]
2. Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX).
Schlech BA; Alfonso E
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S7-15. PubMed ID: 16257313
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone.
Stroman DW; Dajcs JJ; Cupp GA; Schlech BA
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S16-31. PubMed ID: 16257308
[TBL] [Abstract][Full Text] [Related]
4. Ophthalmic infections and their anti-infective challenges.
Alfonso E; Crider J
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S1-6. PubMed ID: 16257307
[TBL] [Abstract][Full Text] [Related]
5. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo.
Caballero AR; Marquart ME; O'Callaghan RJ; Thibodeaux BA; Johnston KH; Dajcs JJ
Curr Eye Res; 2006 Jan; 31(1):23-9. PubMed ID: 16421016
[TBL] [Abstract][Full Text] [Related]
7. Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model.
Kowalski RP; Romanowski EG; Mah FS; Yates KA; Gordon YJ
Am J Ophthalmol; 2005 Sep; 140(3):497-504. PubMed ID: 16083841
[TBL] [Abstract][Full Text] [Related]
8. Evidence-based review of moxifloxacin.
O'Brien TP
Int Ophthalmol Clin; 2006; 46(4):61-72. PubMed ID: 17060792
[No Abstract] [Full Text] [Related]
9. Safety of moxifloxacin as shown in animal and in vitro studies.
McGee DH; Holt WF; Kastner PR; Rice RL
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S46-54. PubMed ID: 16257310
[TBL] [Abstract][Full Text] [Related]
10. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans.
Robertson SM; Curtis MA; Schlech BA; Rusinko A; Owen GR; Dembinska O; Liao J; Dahlin DC
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S32-45. PubMed ID: 16257309
[TBL] [Abstract][Full Text] [Related]
11. Clinical safety of moxifloxacin ophthalmic solution 0.5% (VIGAMOX) in pediatric and nonpediatric patients with bacterial conjunctivitis.
Silver LH; Woodside AM; Montgomery DB
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S55-63. PubMed ID: 16257311
[TBL] [Abstract][Full Text] [Related]
12. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones.
Hwang DG
Surv Ophthalmol; 2004 Mar; 49 Suppl 2():S79-83. PubMed ID: 15028483
[TBL] [Abstract][Full Text] [Related]
13. Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients.
Espiritu CR; Caparas VL; Bolinao JG
J Cataract Refract Surg; 2007 Jan; 33(1):63-8. PubMed ID: 17189795
[TBL] [Abstract][Full Text] [Related]
14. Ophthalmic antibiotics and antimicrobial resistance a randomized, controlled study of patients undergoing intravitreal injections.
Kim SJ; Toma HS
Ophthalmology; 2011 Jul; 118(7):1358-63. PubMed ID: 21420176
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 2 moxifloxacin regimens for preoperative prophylaxis: prospective randomized triple-masked trial. Part 2: residual conjunctival flora.
Vasavada AR; Gajjar D; Raj SM; Vasavada V; Vasavada V
J Cataract Refract Surg; 2008 Aug; 34(8):1383-8. PubMed ID: 18655992
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery.
Lane SS; Osher RH; Masket S; Belani S
J Cataract Refract Surg; 2008 Sep; 34(9):1451-9. PubMed ID: 18721703
[TBL] [Abstract][Full Text] [Related]
17. Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin.
O'Brien TP; Arshinoff SA; Mah FS
J Cataract Refract Surg; 2007 Oct; 33(10):1790-800. PubMed ID: 17889778
[TBL] [Abstract][Full Text] [Related]
18. The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis.
Benitez-Del-Castillo J; Verboven Y; Stroman D; Kodjikian L
Clin Drug Investig; 2011; 31(8):543-557. PubMed ID: 21604820
[TBL] [Abstract][Full Text] [Related]
19. One-day application of topical moxifloxacin 0.5% to select for fluoroquinolone-resistant coagulase-negative Staphylococcus.
He L; Ta CN; Miño de Kaspar H
J Cataract Refract Surg; 2009 Oct; 35(10):1715-8. PubMed ID: 19781465
[TBL] [Abstract][Full Text] [Related]
20. A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis.
Granet DB; Dorfman M; Stroman D; Cockrum P
J Pediatr Ophthalmol Strabismus; 2008; 45(6):340-9. PubMed ID: 19043945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
